Marizyme press releases
WebFORT COLLINS, Colo., March 18, 2024 (Newswire.com) - Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space and related areas, announced today that they signed a Letter of Intent to evaluate the licensing or acquisition of certain non-opiate pain … Web11 jan. 2024 · JUPITER, Fla., Jan. 11, 2024 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue...
Marizyme press releases
Did you know?
WebMARIZYME, INC. press releases Other OTC: GBSX Other OTC Web5 jan. 2024 · MRZM Press Releases Published Jan 5, 2024 Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office Published Dec 23, 2024...
Web1 feb. 2024 · JUPITER, Fla., Feb. 1, 2024 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in... Web23 dec. 2024 · JUPITER, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“ Marizyme ” or the “ Company ”) ( OTCQB:MRZM ), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. (TSXV:CHIP.H), along with a concurrent financing.
Web31 mrt. 2024 · JUPITER, Fla., March 31, 2024 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders … WebFORT COLLINS, Colo., March 15, 2024 (Newswire.com) - Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have received FDA feedback regarding their development …
WebJUPITER, Fla., Jan. 7, 2024 /PRNewswire/ -- Marizyme, Inc. ( OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of …
Web31 mrt. 2024 · This press release may contain certain forward-looking statements, including those relating to Marizyme's product development, clinical and regulatory timelines, … the good fight tv series wikiWeb4 dec. 2024 · This press release may contain certain forward-looking statements, including those relating to the Marizyme's product development, clinical and regulatory timelines, … the good fight tv show cancelledWeb24 jan. 2024 · MARIZYME INC. Weekly Stock ListIn 1Q23, stocks continued to recover from the bear-market lows of 2024, with the S&P 500 rising 7% for the quarter. ... Press … theaters southgateWeb2 nov. 2024 · Marizyme's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence... the good fight tv series ukWeb4 dec. 2024 · JUPITER, Fla., Dec. 4, 2024 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has expanded the company's executive team and … the good fight tv charactersWebMarizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health … Marizyme, Inc. is a multi-technology biomedical company dedicated to the … the good fight tv show cast season 2Web4 feb. 2024 · JUPITER, Fla., Feb. 4, 2024 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM ), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury... theaters southpoint